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Abstract
Background:  Patient education and self-management programs are offered in many countries to people with chronic
conditions such as osteoarthritis (OA). The most well-known is the disease-specific Stanford Arthritis Self-Management Program
(ASMP). While Australian and international clinical guidelines promote the concept of self-management for OA, there is
currently little evidence to support the use of the ASMP. Several meta-analyses have reported that arthritis self-management
programs had minimal or no effect on reducing pain and disability. However, previous studies have had methodological
shortcomings including the use of outcome measures which do not accurately reflect program goals. Additionally, limited cost-
effectiveness analyses have been undertaken and the cost-utility of the program has not been explored.
Methods/design: This study is a randomised controlled trial to determine the efficacy (in terms of Health-Related Quality of
Life and self-management skills) and cost-utility of a 6-week group-based Stanford ASMP for people with hip or knee OA.
Six hundred participants referred to an orthopaedic surgeon or rheumatologist for hip or knee OA will be recruited from
outpatient clinics at 2 public hospitals and community-based private practices within 2 private hospital settings in Victoria,
Australia. Participants must be 18 years or over, fluent in English and able to attend ASMP sessions. Exclusion criteria include
cognitive dysfunction, previous participation in self-management programs and placement on a waiting list for joint replacement
surgery or scheduled joint replacement.
Eligible, consenting participants will be randomised to an intervention group (who receive the ASMP and an arthritis self-
management book) or a control group (who receive the book only). Follow-up will be at 6 weeks, 3 months and 12 months
using standardised self-report measures. The primary outcome is Health-Related Quality of Life at 12 months, measured using
the Assessment of Quality of Life instrument. Secondary outcome measures include the Health Education Impact Questionnaire,
Western Ontario and McMaster Universities Osteoarthritis Index (pain subscale and total scores), Kessler Psychological
Distress Scale and the Hip and Knee Multi-Attribute Priority Tool. Cost-utility analyses will be undertaken using administrative
records and self-report data. A subgroup of 100 participants will undergo qualitative interviews to explore the broader potential
impacts of the ASMP.
Discussion: Using an innovative design combining both quantitative and qualitative components, this project will provide high
quality data to facilitate evidence-based recommendations regarding the ASMP.
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Background
Osteoarthritis (OA) is a common chronic disease that
poses particular challenges to patients and health profes-
sionals as there is currently no cure for the condition.
Consequently, the majority of chronic disease care and
management is undertaken by the individual who may
only have brief and infrequent interactions with the
health care system. Effective management of OA therefore
requires self-management of the condition. Patient educa-
tion programs aim to impart knowledge and skills to indi-
viduals so that they may better manage their arthritis. A
widely-recognised program is the Arthritis Self-Manage-
ment Program (ASMP), developed at the Stanford Univer-
sity Medical Centre in the early 1980s by Lorig and
colleagues [1]. The program addresses pain management,
healthy behaviours, communication with doctors and dis-
ease-specific information [2]. An important aspect of the
program is the bringing together of individuals in a simi-
lar situation for mutual support and to foster a sense of
self-efficacy [3,4]. Self-efficacy is based on social cognitive
theory [5] and relates to an individual's confidence and
ability to perform healthy behaviours.
Osborne et al [6] described the core concepts promoted in
patient self-management as:
• engagement in activities which promote health, build
physiological reserve, and prevent adverse sequelae;
￿ appropriate interaction with healthcare providers and
adherence to recommended treatments;
￿ monitoring of physical and emotional status and mak-
ing appropriate management decisions on the basis of the
results of self-monitoring; and
￿ management of the effects of illness on an individual's
emotions, self-esteem, relationships with others and abil-
ity to function in important roles.
A key criticism of previous studies evaluating the ASMP is
the use of outcome measures which do not accurately
reflect the goals of the programs. Table 1 presents the
pooled effect sizes from recent meta-analyses of studies
evaluating self-management education programs (not
restricted to the Stanford ASMP). Earlier studies have
focussed on measures of pain and disability [7-9], which
overall, have remained unchanged or only slightly
improved after self-management programs. A small bene-
ficial effect of self-management on psychological out-
comes was reported [10]; although only 3 studies used the
Stanford ASMP model and variability in the individual
effect sizes (range -0.19 to 0.33) means that firm conclu-
sions cannot be drawn. Most recently, a large study con-
ducted in the United Kingdom reported significant
improvements in anxiety and self-efficacy following an
arthritis self-management program, although the mean
gains were small and unlikely to be clinically important
[11].
As non-specific chronic disease self-management pro-
grams have been found to be beneficial for other patient
groups in terms of reduced blood pressure, fewer asthma
attacks and lower blood glucose levels [8,9], it is likely
that the outcomes of the ASMP are yet to be appropriately
and comprehensively assessed. This is supported by New-
man et al [12], who considered that the ASMP was prima-
rily directed towards strategies to cope with symptoms
and their sequelae, rather than the reduction of pain and
disability. Thus, the ASMP focuses on changing an indi-
vidual's perceptions of pain and the development of strat-
egies to manage the disabling effects of arthritis. The
intended impact of the program would therefore be better
described as improving an individual's self-management
skills set, enhancing their knowledge of arthritis and
appropriate use of healthcare and further down the causal
chain, improving their Health-Related Quality of Life
(HRQoL). These constructs have been poorly-measured to
date but could provide valuable information about the
potential broader impacts of the ASMP.
Table 1: Pooled effect sizes from published meta-analyses evaluating self-management programs for arthritis
Outcome Meta-analysis Number of studies Pooled effect size (95%CI) Interpretation
Pain Warsi et al 2003 [7] 16 0.12 (0.00 to 0.24) No effect
Warsi et al 2004 [8] 16 0.12 (0.00 to 0.24) No effect
Chodosh et al 2005 [9] 14 -0.06 (-0.10 to -0.02) Small effect, favours intervention group
Disability Warsi et al 2003 [7] 12 0.07 (0.00 to 0.15) No effect
Warsi et al 2004 [8] 12 0.07 (0.00 to 0.15) No effect
Chodosh et al 2005 [9] 12 -0.06 (-0.10 to -0.02) Small effect, favours intervention group
Physical outcomes* Devos-Comby et al 2006 [10] 12 0.09 (-0.01 to 0.19) No effect
Psychological outcomes† Devos-Comby et al 2006 [10] 9 0.20 (0.08 to 0.33) Small effect, favours intervention group
Impairment# Devos-Comby et al 2006 [10] 3 0.04 (-0.25 to 0.34) No effect
*Includes measures of pain, disability, physical functioning, arthritis impact and mobility [10]
†Includes measures of psychological disability, mental functioning, self-efficacy and depressive symptoms [10]
#Includes physiological measures and performance tests [10]BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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Another limitation of earlier studies investigating the
ASMP has been the use of unrepresentative samples.
Much of the initial research was undertaken by the devel-
opers of the ASMP using randomised convenience sam-
ples recruited from the community [1,13]. Such samples
are unlikely to be representative of the wider population
with OA, particularly with respect to the level of education
attained. For example, the largest study included 695 indi-
viduals where 73% of the sample had more than 12 years
of education and of these, 29% had more than 16 years of
education [13]. Previous studies have used heterogeneous
study samples which have included people with OA, rheu-
matoid arthritis and fibromyalgia [7]. Further research
involving representative and well-characterised samples is
required to improve the generalisability of the results.
Although current Australian and international clinical
guidelines promote the concept of self-management for
osteoarthritis [14,15], there is presently little evidence to
support the ASMP. This lack of evidence may be a barrier
to clinicians referring patients to the program. Our earlier
research has shown that ASMPs are under-utilised by peo-
ple with arthritis and that only a small proportion of self-
management referrals come from health professionals
[6,16]. While the ASMP has been applied in some com-
munity settings for many years, its overall impact on the
wellbeing of people with OA remains unknown. The
present study will provide much-needed data on the effi-
cacy of the ASMP with respect to HRQoL and self-manage-
ment skills sets; it will also evaluate the cost-utility and
applicability of this intervention for people with lower
limb OA.
Methods/design
Aim
The primary aim of this study is to determine the efficacy
of a 6-week, group-based ASMP on HRQoL and self-man-
agement skills in people with hip or knee OA.
Study design
This study is a randomised controlled trial with a 12
month follow-up period. Although the blinding of partic-
ipants would be ideal, we did not consider this feasible as
the possibility of attending a 6 week program needs to be
explained to potential participants in order to ascertain
their willingness to take part in the study.
In the present study, participants will be allocated to an
intervention group who will undergo the Stanford ASMP
and receive an arthritis self-management book [2] or to a
control group who will receive the book only. The study
has both quantitative and qualitative components; an
overview of the recruitment method, randomisation proc-
ess and follow-up procedures is provided in Figures 1 and
2.
Ethics
Ethics approval has been received from the Human
Research Ethics Committees of Barwon Health, Cabrini
Hospital, Epworth Hospital and The University of Mel-
bourne.
Eligibility criteria
The eligibility criteria for this study are listed in Table 2.
Determination of eligibility will involve a two-step proc-
ess commencing with review of the potential participant's
medical record and subsequent telephone screening. A
diagnosis of hip or knee OA will be extracted from radiol-
ogy reports; where this information is not stated explicitly,
medical records and radiographs will be used to diagnose
OA according to American College of Rheumatology crite-
ria [17,18]
Identification and recruitment of study participants
Six hundred participants referred to an orthopaedic sur-
geon or rheumatologist for hip or knee OA will be
recruited from outpatient clinics at 2 public hospitals and
community-based private practices located within 2 pri-
vate hospital settings in Victoria, Australia. Potentially eli-
gible individuals will be identified by both retrospective
review of recent medical records and prospective identifi-
cation of consecutive presentations attending orthopaedic
surgeons and rheumatologists associated with the study
hospitals. Due to differences in the structure of public and
private health care systems in Australia, the recruitment
procedure at each of the sites will be slightly different. At
the private practices, identification of potentially eligible
participants will be undertaken by the treating specialist
and a letter inviting participation will be provided. Writ-
ten consent will be required before contact can be made
by the researchers. At the public hospital sites, potentially
eligible participants will be sent an information letter and
then contacted by a researcher. The recruitment and
screening process is summarised in Figure 2.
A researcher will then telephone potentially eligible par-
ticipants to provide detailed information about the study.
At this time, a screening form will be completed to verify
that the individual meets the eligibility criteria. Potential
participants will be asked about their preferences for
ASMPs with respect to scheduling and the preferred for-
mat of the program (eg 6-week course or provision of a
book). Individuals who do not provide verbal consent
will be asked to list up to three reasons for not participat-
ing in the study. This information will be used to estimate
the feasibility of conducting the ASMP in a 'real world' set-
ting and for translating the program into clinical practice.
People who meet the specified eligibility criteria and pro-
vide verbal consent will then be sent a consent form and
baseline questionnaire.BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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Study design and assessment points Figure 1
Study design and assessment points.
Intervention group (n=300) Control group (n=300)
3 month questionnaire 
(all instruments)
Randomisation 
Baseline questionnaire 
End of study 
6 week questionnaire 
(heiQ and MAPT only)
12 month questionnaire 
(all instruments)
No interview 
(n=250)
Initial and 6 
week interviews 
(n=25)
6 week interview 
only 
(n=25)
No interview 
(n=250)
Initial and 6 
week interviews 
(n=25)
6 week interview 
only 
(n=25)
Initial interview 
(n=25)
Initial interview 
(n=25)
6-week ASMP and book Book only
6 week interview 
(n=50)
6 week interview
(n=50)
Randomisation  Randomisation BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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Identification and recruitment of study participants Figure 2
Identification and recruitment of study participants.
Verbal consent given?
YES
Participant Information & 
Consent Form and baseline 
questionnaire mailed
Potentially eligible patients identified 
through review of outpatient 
orthopaedic & rheumatology medical 
records by research staff 
Introductory letter provided to 
potentially eligible patients
Researcher contacts patient to 
provide further information and 
complete screening form
Introductory letter provided to 
potentially eligible patients
Public hospital sites Private hospital sites
Patient completes and signs 
contact details form 
Patient does not complete and 
sign contact details form 
No contact made
NO
No further contact made
Participant enters study and is 
randomised
Participant Information & 
Consent Form and baseline 
questionnaire returned
Potentially eligible patients identified 
through review of medical records by 
orthopaedic surgeons/rheumatologists 
and consecutive attendances BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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Randomisation
Once a completed consent form and baseline question-
naire have been returned to the researchers, the partici-
pant is considered to have entered the study and will be
randomised to either the intervention or control groups,
stratified by study site. For each site, a computer-generated
random numbers table will be used to assign group allo-
cation according to permuted blocks of 4 or 6. A second
randomisation procedure, stratified by treatment group,
will be used to select a subgroup of 100 participants who
will undergo up to 2 qualitative telephone interviews
(conducted at baseline and 6 weeks, or 6 weeks only).
Group allocation will be concealed using opaque sealed
envelopes. Upon receipt of a completed consent form and
baseline questionnaire, the group allocation envelope will
be opened at the study co-ordinating centre (Centre for
Rheumatic Diseases, The University of Melbourne) by a
research assistant not associated with this study. To fur-
ther ensure the integrity of the treatment allocation, this
process will be observed by a second staff member and
recorded with a signature and date. At this point, partici-
pants will be informed of their group allocation.
Intervention
The active intervention group will take part in the Stan-
ford ASMP. The program consists of a weekly 2.5 hour ses-
sion for 6 weeks. The program will be held in a variety of
locations in metropolitan Melbourne and Geelong and at
a variety of times (day, evening, weekday and weekend) to
maximise attendance. Each course will have up to 12 par-
ticipants. The course is delivered in a prescriptive format
by two leaders and covers the following key areas [6]:
￿ management of pain and fatigue
￿ physical activity
￿ medication usage
￿ managing anger, fear and frustration
￿ solving health-related problems
￿ communication with doctors
For this study, one peer leader (who has arthritis or per-
sonal experience of arthritis) and one health professional
leader (for example, a nurse or physiotherapist) will be
used. This model has worked well in our pilot research
and anecdotal reports indicate that this method may be
preferred by referring clinicians. Course leaders who have
undergone training in the Stanford ASMP model will be
recruited and additional leaders (where required) will be
trained according to the Stanford course leader protocol.
Regular course leader meetings will be held to ensure
standardised leader quality and high retention rates.
Participants will also receive an arthritis self-management
book [2]. Although the primary component of the ASMP
is group-based education and close interaction with 'like'
individuals, the course also encourages directed home-
based learning and practice of skills learned in the ses-
sions. These activities are supported by the arthritis self-
management book.
Control
The control group will not receive the ASMP but will be
sent an arthritis self-management book [2]. There is cur-
rently no evidence to suggest that provision of this book
alone is beneficial, although to date, this has only been
assessed in one study which investigated the effect of the
ASMP for people with OA, rheumatoid arthritis or fibro-
myalgia [19]. After 4 months, no change in pain, self-effi-
cacy, disability or mental health was observed for the
control group which received the Arthritis Self-Help book
only.
Outcome measures
Participants will be assessed using a range of standardised,
self-report measures which include:
1. The Assessment of Quality of Life (AQoL) instrument
The primary outcome for this RCT is HRQoL at 12
months, as measured by the AQoL instrument. This out-
come was chosen to reflect the potential longer-term ben-
efits of the multi-faceted ASMP [6]. The AQoL instrument
Table 2: Eligibility criteria
Inclusion criteria Exclusion criteria
• aged 18 years or over • cognitive dysfunction
• diagnosis of hip or knee OA* • previous participation in an ASMP or similar program
• referred to an orthopaedic surgeon or rheumatologist for hip or knee OA • placement on an orthopaedic waiting list for joint replacement surgery or scheduled 
joint replacement surgery
• sufficient English language skills to self-complete written questionnaires
• a reasonable expectation that all 6 sessions of the ASMP could be attended if 
randomised to the intervention group
*A diagnosis of hip or knee OA will be extracted from radiology reports; where this information is not stated explicitly, medical records and 
radiographs will be used to diagnose OA according to American College of Rheumatology criteria [17, 18]BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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is an Australian generic utility tool which can be used for
health economic evaluation through estimation of utili-
ties and calculation of Quality-Adjusted Life Years
(QALYs). The four dimensions covered by this instrument
include Independent Living, Social Relationships, Physi-
cal Senses and Psychological Wellbeing. The AQoL instru-
ment has strong psychometric properties and is more
sensitive and responsive than many other widely-used
scales including the Medical Outcomes Study 36-Item
Short Form (SF-36) [20,21]. The AQoL utility score ranges
from -0.04 (worst possible HRQoL) to 1.00 (full HRQoL).
A minimal important difference for the AQoL instrument
is considered to be between 0.03 and 0.08 AQoL units
[22]. For the present study, an increase of 0.05 AQoL units
will be regarded as a clinically important improvement in
HRQoL.
2. The Health Education Impact Questionnaire (heiQ)
The heiQ was developed to evaluate the intended effects
of self-management programs and was found to be relia-
ble and responsive to change in an Australian validation
study [6,23]. It has since been administered to over 1300
Australians with chronic conditions who have attended
self-management programs [24]. The heiQ contains 42
questions and covers 8 dimensions which include: Posi-
tive and active engagement in life, Health behaviour
change, Skill and technique acquisition, Constructive atti-
tudes and approaches, Self monitoring and insight,
Health service navigation, Social integration and Emo-
tional wellbeing. Each dimension produces an overall
score from 1 (strongly disagree) to 6 (strongly agree).
3. The Western Ontario and McMaster Universities OA (WOMAC) 
Index
The WOMAC Index is a disease-specific measure of health
status and is widely used in OA research. The validity, reli-
ability and responsiveness of this measure have been
demonstrated in an extensive range of studies [25]. The
WOMAC Index consists of 24 questions which cover pain,
stiffness and fatigue and produces a total score which can
be transformed to a 0 (best possible health) to 100 (worst
possible health) scale. The pain subscale score will also be
reported.
4. The Kessler Psychological Distress Scale (K10)
The K10 instrument provides a measure of psychological
distress [26] and is used in the World Health Organisation
World Mental Health Survey and Australian population
health surveys. High K10 scores representing high distress
are strong predictors of affective disorders such as depres-
sion and anxiety [27]. The scale has demonstrated discri-
minant validity in United States National Health
Interview Surveys [26]. The K10 consists of 10 questions
about anxiety, depression and worry and produces a total
score ranging from 10 (lowest psychological distress) to
50 (highest psychological distress).
5. The Hip and Knee Multi-Attribute Priority Tool (MAPT)
The MAPT was designed as a measure of arthritis disease
severity [28]. The MAPT was developed through extensive
consultation with patients, orthopaedic surgeons and
other health professionals. The MAPT contains 11 items
which cover areas such as self-care, enjoyment of life, the
economic impact of arthritis and deterioration. A valida-
tion study involving over 900 people with hip or knee
arthritis demonstrated construct validity, good test-retest
reliability and responsiveness to change [28]. The MAPT
produces a score from 0 (least disease severity) to 100
(greatest disease severity).
6. Health services use
The (self-reported) number of visits to health profession-
als during the previous month will be collected from all
participants. The costs of consulting health professionals
will be calculated using published prices for medical and
allied health costs. Additionally, if specific consent is pro-
vided, Australian Health Insurance Commission data will
also be obtained regarding the use and cost of prescription
medications, medical consultations, pathology tests and
hospitalisations during the study period.
7. Community services use
Information about the use of both paid and unpaid com-
munity assistance (for example, home help and Meals on
Wheels) will also be collected by postal survey.
Follow-up procedures
Participants will receive follow-up questionnaires at 6
weeks (heiQ and MAPT instruments only), 3 months (full
range of instruments) and 12 months (full range of instru-
ments). Reply-paid envelopes will be provided to maxim-
ise response rates. At each follow-up assessment,
participants will be asked whether they have attended an
Arthritis Self-Management Program since entering the
study to detect potential cross-over from the control
group.
Qualitative component
Recent research suggests that questionnaire-based out-
come assessment may not accurately reflect people's expe-
riences of chronic disease self-management [29,30].
Given these findings, this study will incorporate an addi-
tional qualitative component to corroborate the question-
naire-based data collected and to elicit detailed
information about participants' expectations of the ASMP
and perceived outcomes following the program. A sub-
group of 100 participants will be selected for the qualita-
tive component. A Solomon four-group design will be
used to minimise the potential impact of behaviouralBMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
Page 8 of 10
(page number not for citation purposes)
changes prompted by the interviews [31,32]. This design
incorporates two groups of participants who do not
undergo a baseline interview, allowing both the potential
effect of the intervention and the potential effect of the
interview to be evaluated. As illustrated in Figure 1, 50
participants will undergo both baseline and 6 week inter-
views (25 participants from the intervention group and 25
participants from the control group). A further 50 partici-
pants (25 from the intervention group and 25 from the
control group) will undergo interviews at 6 weeks only.
The semi-structured telephone interviews (approximately
1 hour in duration) will be conducted by two researchers
trained in qualitative interview techniques.
The qualitative interviews may also reveal the presence of
'response shift', a potential change in perspective as a
result of attending the ASMP [30,33]. Response shift has
been purported to confound the traditional pre-post
assessment methods used to evaluate the outcomes of
health care interventions. In the context of self-manage-
ment education programs, response shift may arise when
a person re-evaluates themselves after a program (retro-
spectively) as being better or worse before the course than
they had thought. Response shift can be categorised as
negative (when a person realises they were worse before
the course than they had first thought) or positive (when
a person realises they were better before the course than
they had first thought). In a study of 39 people who com-
pleted an arthritis or chronic disease self-management
program, Osborne et al [30] found that 31% experienced
a negative response shift, while 20% experienced a posi-
tive response shift. The effect of this change in perspective
on outcomes such as HRQoL has not yet been explored
and will be evaluated in this study by comparing qualita-
tive and quantitative data.
Sample size considerations
The sample size calculations for this study are based on
the primary outcome measure (AQoL instrument). Our
pilot research involving people with OA (n = 39) showed
a mean (SD) improvement in the 6-month AQoL score of
0.04 (0.21) following the ASMP. Given that some of this
sample had end-stage joint disease for which conservative
management was unlikely to be effective, we expect the
effect of the ASMP to be larger than this in people with less
severe OA. It is also important to note that the proportion
of participants who reported a substantial benefit (an
increase in AQoL score of greater than 0.05 utility units)
was about 43%, whereas substantial decline occurred in
20% of participants. Using the proportion of people who
report an improvement of more than 0.05 AQoL utility
units as an outcome, a sample size of 600 (300 partici-
pants in each group) will provide sufficient power to
detect an additional 10% of participants in the interven-
tion group reporting a minimal important improvement
(assuming 30% of control group who report improve-
ment, beta = 0.80, alpha = 0.05, two-tailed).
No data are available on the proportion of people who
might experience a clinically important improvement in
HRQoL over the study period without receiving the active
intervention, although earlier RCTs conducted by the
developers of the ASMP have found minimal improve-
ment for no-treatment control groups for up to 1 year
(average improvement <2% for pain and <1% for depres-
sion) [34,35]. Based on the findings of Solomon et al [19],
provision of the arthritis self-management book to the
control group in the present study is anticipated to have a
negligible impact. However, given the labile nature of OA,
it is possible that the control group may experience fluctu-
ations in wellbeing over the study period. Therefore, a
10% advantage for the intervention group is considered to
be a conservative estimate of benefit.
Planned statistical and qualitative analyses
An intention-to-treat analysis will be performed using all
randomised participants who provide any post-baseline
data [36].
The intervention and control groups will be examined for
baseline comparability with respect to demographic and
other factors. Analysis of covariance will be used to assess
differences in 12 month outcomes between groups after
adjusting for baseline differences. Repeated measures
analysis using linear mixed models will assess the con-
stancy of any effects of the ASMP over time.
A cost-utility analysis will be undertaken as part of this
research. Standard economic evaluation for clinical trials
will be used to assess differences in resource use and
health outcomes between groups [37]. The incremental
cost or savings per extra person with a clinically significant
improvement per Quality-Adjusted Life Year (QALY)
compared to the control group will also be calculated. A
clinically significant improvement in HRQoL will be
regarded as a utility change of at least 0.05 AQoL units
[22].
Qualitative analysis techniques will be used for data
obtained from the telephone interviews. Interview tapes
will be transcribed for analysis; coding of transcripts and
any supplementary written notes will be performed using
codes developed from the data. Data analysis will be
ongoing and will run parallel to the data collection with
the objective being to transcribe data from the interview
before moving onto the next interview (where feasible).
Thematic analysis from the transcripts will be used and
results will be discussed according to themes identified
from the data.BMC Musculoskeletal Disorders 2006, 7:90 http://www.biomedcentral.com/1471-2474/7/90
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Time frame
This study has a 3 year time frame. It is anticipated that
identification of potential study participants and recruit-
ment will commence in October 2006. Follow-up assess-
ment will continue until July 2008, after which time data
analysis will be performed and a final report will be
drafted.
Discussion
In Australia, the ASMP is highly endorsed by Arthritis
Foundations and government agencies, yet the evidence
base to justify this support is very weak. International clin-
ical guidelines together with United States and Australian
National Arthritis Action Plans provide clear statements
that people with OA should be referred to self-manage-
ment courses as part of routine clinical practice. However,
good quality data from OA-specific clinical trials are not
available to justify these recommendations.
This project will provide high quality data to facilitate evi-
dence-based recommendations regarding the ASMP. The
study population is well-defined and likely to be repre-
sentative of the target group who might be expected to
benefit from the ASMP. The course leaders will be highly
trained and the course quality will be tightly controlled.
Finally, the outcome measures to be used in this study
were selected to encompass key data for a wide range of
stakeholders including consumers, clinicians, policymak-
ers and funding bodies.
If the study demonstrates that the ASMP is effective, this
will support referral to the program by clinicians caring
for people with OA. Endorsement of the ASMP by medical
professionals could result in a relatively inexpensive
modality being made more readily available to the mil-
lions of Australians suffering from OA. Furthermore, if
this research finds the ASMP to be effective, it will provide
governmental agencies and non-government organisa-
tions with evidence to facilitate the appropriate dissemi-
nation of this program. In contrast, if the program is not
found to be effective then the resources spent in this area
could be re-directed to other evidence-based interven-
tions.
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